NERVGEN PHARMA CORP. amends financials
- Amended financial statements for 3 months and 6 months ended June 30, 2026 and 2025
- Corrective adjustments for stock options and warrant liabilities
- No impact on cash position or liquidity
NGENF
NERVGEN PHARMA CORP. SEC filings
Every EDGAR filing for NERVGEN PHARMA CORP. (NGENF), newest first, with AI summaries and stories.
- Ticker
- NGENF
- CIK
- 1751912
- Latest filing
- 2d
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINE6-K/ANERVGEN PHARMA CORP.NGENFLIVE ROUTINE40-F/ANERVGEN PHARMA CORP.NGENFLIVE NERVGEN PHARMA CORP files 40-F/A
- Filed on 2026-10-16
- Amended annual report for 2025
- Corrected financial statement errors
ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINESUPPLNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINEEFFECTNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINESUPPLNERVGEN PHARMA CORP.NGENFLIVE ROUTINEF-XNERVGEN PHARMA CORP.NGENFLIVE ROUTINEF-10NERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINESUPPLNERVGEN PHARMA CORP.NGENFLIVE ROUTINESUPPLNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINES-8NERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE NOTABLE40-FNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINES-8NERVGEN PHARMA CORP.NGENFLIVE ROUTINE6-KNERVGEN PHARMA CORP.NGENFLIVE ROUTINEEFFECTNERVGEN PHARMA CORP.NGENFLIVE ROUTINECERTNERVGEN PHARMA CORP.NGENFLIVE ROUTINE8-A12BNERVGEN PHARMA CORP.NGENFLIVE ROUTINEF-10/ANERVGEN PHARMA CORP.NGENFLIVE ROUTINEF-XNERVGEN PHARMA CORP.LIVE ROUTINEF-10NERVGEN PHARMA CORP.LIVE